{"id":"NCT00538915","sponsor":"ADMA Biologics, Inc.","briefTitle":"Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)","officialTitle":"Open Label, Phase III Safety, Efficacy, and Pharmacokinetic Study of NABI-IGIV 10% [Immune Globulin Intravenous (Human), 10%] in Subjects With Primary Immune Deficiency Disorders (PIDD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2009-07","completion":"2009-07","firstPosted":"2007-10-03","resultsPosted":"2012-03-26","lastUpdate":"2021-07-30"},"enrollment":63,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immune Deficiency Disorders (PIDD)"],"interventions":[{"type":"BIOLOGICAL","name":"Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]","otherNames":[]}],"arms":[{"label":"Nabi-IGIV Infused Every 3- or 4-Weeks","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine if NABI-IGIV (10%) \\[Immune Globulin Intravenous (Human), 10%\\] is safe and effective in preventing serious bacterial infections (SBIs) in the treatment of patients with primary immune deficiency disorders (PIDD) when compared to historical control data.","primaryOutcome":{"measure":"Rate of Serious Bacterial Infections (SBIs) Per Person-year on Treatment","timeFrame":"One year","effectByArm":[{"arm":"Nabi-IGIV 10% Administered On A 3-Week or 4-Week Interval","deltaMin":0.035,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":14},"locations":{"siteCount":17,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":63},"commonTop":["Headache","Fatigue","Nausea","Infusion Site Reaction","Sinusitis"]}}